Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

The Identification of Indacaterol as an Ultra-Long-Acting Inhaled Beta-2-Adrenoceptor Agonist

Beattie, David and Beer, David and Bentley, David and Bradley, Michelle and Bruce, Ian and Charlton, Steven and Cuenoud, Bernard and Ernst, Roland and Fairhurst, Robin and Faller, Bernard and Farr, David Colin and Keller, Thomas and Fozard, John R. and Fullerton, Joe and Garman, Sheila and Hatto, Julia and Hayden, Claire and He, Handan and Howes, Colin and Janus, Diana and Jiang, Zhengjin and Loeuillet-Ritzler, Frederique and Moser, Heinz and Reilly, John and Steward, Alan and Sykes, David and Tedaldi, Lauren and Trifilieff, Alexandre and Tweed, Morris and Watson, Simon and Wissler, Elke and Wyss, Daniel and Baur, Francois and Charman, Christine (2010) The Identification of Indacaterol as an Ultra-Long-Acting Inhaled Beta-2-Adrenoceptor Agonist. Journal of Medicinal Chemistry, 53. pp. 3675-3684.

Abstract

Following a lipophilicity-based hypothesis, a series of 2-aminoindan and 8-hydroxyquinolinone derived 2-adrenoceptor agonists have been prepared and evaluated for their potential as inhaled ultra-long-acting bronchodilators. Determination of their activities at the human 2-adrenoceptor receptor showed symmetrical substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clinical reference 2-adrenoceptor agonists. Further assessment with an in vitro super-fused electrically-stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses which could be rationalised by considering the lipophilicity, potency and intrinsic efficacy of the compounds. From these studies the 5,6-diethylindan analogue indacaterol 1c was shown to possess a unique profile of combining a rapid onset of action with a long duration of action. Further in vivo profiling of 1c supported the long duration of action and a wide therapeutic index following administration to the lung which led to the compound being selected as a development candidate.

Item Type: Article
Related URLs:
Keywords: beta-2 adrenoceptor agonists, asthma, COPD, inhalation, long-acting
Related URLs:
Date Deposited: 13 Oct 2015 13:16
Last Modified: 13 Oct 2015 13:16
URI: https://oak.novartis.com/id/eprint/1954

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.